AAHKS最佳口头报告研究奖:骨内注射万古霉素降低无菌性翻修全膝关节置换术后假体周围关节感染发生率
单机构回顾性研究纳入2016年5月至2023年10月无菌性翻修全膝关节置换术患者,比较骨内注射万古霉素(333例)与静脉注射万古霉素(386例)对假体周围关节感染的影响。骨内组30天、90天和1年假体周围关节感染发生率均显著低于静脉组,两组不良事件无差异。
要点
- 骨内组30天假体周围关节感染发生率为0.3%,静脉组为2.1%(P=0.03)。
- 骨内组90天假体周围关节感染发生率为0.9%,静脉组为3.1%(P=0.04)。
- 骨内组1年假体周围关节感染发生率为1.6%,静脉组为4.9%(P=0.04)。
核心结论
- 骨内注射万古霉素是无菌性翻修全膝关节置换术患者静脉给药的安全有效替代方案。
- 骨内注射万古霉素优化了该高危手术队列中万古霉素给药的效率,并在1年随访期内显著降低了假体周围关节感染发生率。
研究设计与样本
- 单机构回顾性综述,纳入2016年5月至2023年10月接受无菌性翻修全膝关节置换术的患者。
- 静脉组386例,骨内组333例;静脉组在皮肤切开前接受15 mg/kg剂量万古霉素,骨内组在止血带充气后经胫骨注入500 mg万古霉素。
- 所有患者围手术期还接受基于体重的静脉头孢唑林剂量。
主要发现
- 骨内组30天假体周围关节感染发生率为0.3%,静脉组为2.1%(P=0.03)。
- 骨内组90天假体周围关节感染发生率为0.9%,静脉组为3.1%(P=0.04)。
- 骨内组1年假体周围关节感染发生率为1.6%,静脉组为4.9%(P=0.04)。
- 未报告万古霉素不良反应。
- 两组急性肾损伤发生率无差异(骨内组2.7% vs 静脉组2.9%,P=0.90),深静脉血栓发生率无差异(骨内组1.2% vs 静脉组1.8%,P=0.56),肺栓塞发生率无差异(骨内组0% vs 静脉组0.3%,P=1.0)。
关键数值与推荐
- 假体周围关节感染诊断基于2018年肌肉骨骼感染学会标准。
- 分类结局比较采用Fisher精确检验和卡方分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection (PJI) is a devastating complication following total knee arthroplasty (TKA). Prior literature supports the intraosseous (IO) delivery of vancomycin as a safe and effective technique for primary TKA. The purpose of this study was to evaluate its efficacy for aseptic revision of TKA. METHODS: A single-institution retrospective review was performed on patients who underwent aseptic revision TKA from May 2016 to October 2023. Vancomycin was administered through an intravenous (IV) route in 386 cases and via an IO infusion in 333 cases. The IV cohort received a 15 mg/kg dose of vancomycin before skin incision. The IO cohort received a 500 mg dose of vancomycin infused into the tibia after tourniquet inflation. All patients also received a weight-based dose of IV cefazolin perioperatively. Patient characteristics, surgical details, and infection-related data were extracted during chart review. The PJI diagnosis was based on the 2018 Musculoskeletal Infection Society criteria. Fisher's exact tests and Chi-square analyses were used to compare categorical outcomes. RESULTS: The incidence of PJI was significantly lower in the IO cohort compared to the IV cohort at 30-day (0.3 versus 2.1%, P = 0.03), 90-day (0.9 versus 3.1%, P = 0.04), and 1-year follow-up (1.6 versus 4.9%, P = 0.04). There were no reported adverse reactions to vancomycin. There were no differences in the incidence of acute kidney injury (2.7 versus 2.9%, P = 0.90), deep venous thrombosis (1.2 versus 1.8%, P = 0.56), or pulmonary embolism (0 versus 0.3%, P = 1.0) between groups. CONCLUSIONS: Use of IO vancomycin infusion is a safe and effective alternative to IV administration for patients undergoing aseptic revision TKA. Furthermore, IO vancomycin optimized the efficiency of vancomycin administration in this high-risk surgical cohort and resulted in a significant reduction in the rate of PJI through 1-year follow-up.
引用
- McNamara CA, Wininger AE, Sullivan TC, et al. The AAHKS Best Podium Presentation Research Award: Intraosseous Vancomycin Reduces the Rate of Periprosthetic Joint Infection Following Aseptic Revision Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40339929. doi:10.1016/j.arth.2025.04.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。